1. Otto, CM, Kumbhani, DJ, Alexander, KP, et al. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2017; 69: 1313–1346.
Google Scholar | Crossref | Medline2. Kaul, S . Raising the evidentiary bar for guideline recommendations for TAVR: JACC review topic of the week. J Am Coll Cardiol 2020; 76: 985–991.
Google Scholar | Crossref | Medline3. Dangas, GD, Tijssen, JGP, Wöhrle, J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020; 382: 120–129.
Google Scholar | Crossref | Medline4. Kahlert, P, Knipp, SC, Schlamann, M, et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation 2010; 121: 870–878.
Google Scholar | Crossref | Medline5. Otto, CM, Nishimura, RA, Bonow, RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021; 143: e72–e227.
Google Scholar6. January, CT, Wann, LS, Calkins, H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the society of thoracic surgeons. Circulation 2019; 140: e125–e151.
Google Scholar | Crossref | Medline7. Baumgartner, H, Falk, V, Bax, JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739–2791.
Google Scholar | Crossref | Medline8. Steffel, J, Collins, R, Antz, M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace 2021; 23: 1612–1676.
Google Scholar | Crossref9. Kearon, C, Akl, EA, Ornelas, J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149: 315–352.
Google Scholar | Crossref | Medline10. Hindricks, G, Potpara, T, Dagres, N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373–498.
Google Scholar | Crossref | Medline11. Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research Ed) 2009; 339: b2700.
Google Scholar | Crossref | Medline12. Kappetein, AP, Head, SJ, Généreux, P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012; 60: 1438–1454.
Google Scholar | Crossref | Medline13. Higgins, JP, Altman, DG, Gøtzsche, PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed) 2011; 343: d5928.
Google Scholar | Crossref | Medline14. Slim, K, Nini, E, Forestier, D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003; 73: 712–716.
Google Scholar | Crossref | Medline15. Weis, S, Kesselmeier, M, Davis, JS, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2019; 25: 818–827.
Google Scholar | Crossref | Medline16. De Backer, O, Dangas, GD, Jilaihawi, H, et al. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med 2020; 382: 130–139.
Google Scholar | Crossref | Medline17. Seeger, J, Gonska, B, Rodewald, C, et al. Apixaban in patients with atrial fibrillation after transfemoral aortic valve implantation compared with vitamin K antagonist [Conference abstract]. J Am Coll Cardiol 2016; 68: B92.
Google Scholar18. Butt, JH, Backer, O, Olesen, JB, et al. Vitamin K antagonists versus direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Eur Heart J Cardiovasc Pharmacother 2021; 7: 11–19.
Google Scholar | Crossref | Medline19. Geis, NA, Kiriakou, C, Chorianopoulos, E, et al. NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol 2018; 107: 799–806.
Google Scholar | Crossref | Medline20. Jochheim, D, Barbanti, M, Capretti, G, et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2019; 12: 1566–1576.
Google Scholar | Crossref | Medline21. Kalogeras, K, Jabbour, RJ, Ruparelia, N, et al. Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry [Article]. J Thromb Thrombolysis 2020; 50: 82–89.
Google Scholar | Crossref | Medline22. Kawashima, H, Watanabe, Y, Hioki, H, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR. JACC Cardiovasc Interv 2020; 13: 2587–2597.
Google Scholar | Crossref | Medline23. Kosmidou, I, Liu, Y, Alu, MC, et al. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation. JACC Cardiovasc Interv 2019; 12: 1580–1589.
Google Scholar | Crossref | Medline24. Mangner, N, Crusius, L, Haussig, S, et al. Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation. Am J Cardiol 2019; 123: 1134–1141.
Google Scholar | Crossref | Medline25. Tang, L, Lesser, JR, Schneider, LM, et al. Prospective evaluation for hypoattenuated leaflet thickening following transcatheter aortic valve implantation. Am J Cardiol 2019; 123: 658–666.
Google Scholar | Crossref | Medline26. Yanagisawa, R, Tanaka, M, Yashima, F, et al. Early and late leaflet thrombosis after transcatheter aortic valve replacement: a multicenter initiative from the OCEAN-TAVI registry. Circ Cardiovasc Interv 2019; 12: e007349.
Google Scholar | Crossref | Medline27. Lindman, BR, Clavel, MA, Mathieu, P, et al. Calcific aortic stenosis. Nat Rev Dis Primers 2016; 2: 16006.
Google Scholar | Crossref | Medline28. Peeters, F, Meex, SJR, Dweck, MR, et al. Calcific aortic valve stenosis: hard disease in the heart: a biomolecular approach towards diagnosis and treatment. Eur Heart J 2018; 39: 2618–2624.
Google Scholar | Crossref | Medline29. Schurgers, LJ, Uitto, J, Reutelingsperger, CP. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med 2013; 19: 217–226.
Google Scholar | Crossref | Medline30. Hutcheson, JD, Aikawa, E, Merryman, WD. Potential drug targets for calcific aortic valve disease. Nat Rev Cardiol 2014; 11: 218–231.
Google Scholar | Crossref | Medline31. Vranckx, P, Windecker, S, Welsh, RC, et al. Thrombo-embolic prevention after transcatheter aortic valve implantation. Eur Heart J 2017; 38: 3341–3350.
Google Scholar | Crossref | Medline32. Guedeney, P, Mehran, R, Collet, JP, et al. Antithrombotic therapy after transcatheter aortic valve replacement. Circ Cardiovasc Interv 2019; 12: e007411.
Google Scholar | Crossref | Medline33. Van Mieghem, NM, Schipper, ME, Ladich, E, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation 2013; 127: 2194–2201.
Google Scholar | Crossref | Medline34. Mangieri, A, Montalto, C, Poletti, E, et al. Thrombotic versus bleeding risk after transcatheter aortic valve replacement: JACC review topic of the week. J Am Coll Cardiol 2019; 74: 2088–2101.
Google Scholar | Crossref | Medline35. Chakravarty, T, Søndergaard, L, Friedman, J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet (London, England) 2017; 389: 2383–2392.
Google Scholar | Crossref | Medline36. Sannino, A, Hahn, RT, Leipsic, J, et al. Meta-analysis of Incidence, predictors and consequences of clinical and subclinical bioprosthetic leaflet thrombosis after transcatheter aortic valve implantation. Am J Cardiol 2020; 132: 106–113.
Google Scholar | Crossref | Medline37. Makkar, RR, Fontana, G, Jilaihawi, H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 2015; 373: 2015–2024.
Google Scholar | Crossref | Medline38. Moreno, R, Unverdorben, M, Jurado-Román, A, et al. The risk of valve thrombosis is higher with intra-annular versus supra-annular transcatheter aortic valve prosthesis. A meta-analysis from randomized controlled trials. Clin Res Cardiol. Epub ahead of print 19 February 2021. DOI: 10.1007/s00392-021-01818-x.
Google Scholar | Crossref | Medline39. Piccolo, R, Pilgrim, T, Franzone, A, et al. Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017; 10: 1436–1446.
Google Scholar | Crossref | Medline40. Nkomo, VT, Gardin, JM, Skelton, TN, et al. Burden of valvular heart diseases: a population-based study. Lancet (London, England) 2006; 368: 1005–1011.
Google Scholar | Crossref | Medline41. Villa, JKD, Diaz, MAN, Pizziolo, VR, et al. Effect of vitamin K in bone metabolism and vascular calcification: a review of mechanisms of action and evidences. Crit Rev Food Sci Nutr 2017; 57: 3959–3970.
Google Scholar | Crossref | Medline42. Stenflo, J, Fernlund, P, Egan, W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 1974; 71: 2730–2733.
Google Scholar | Crossref | Medline43. Ivanova, D, Zhelev, Z, Getsov, P, et al. Vitamin K: redox-modulation, prevention of mitochondrial dysfunction and anticancer effect. Redox Biol 2018; 16: 352–358.
Google Scholar | Crossref | Medline44. Ferland, G . The discovery of vitamin K and its clinical applications. Ann Nutr Metab 2012; 61: 213–218.
Google Scholar | Crossref | Medline45. Weijs, B, Blaauw, Y, Rennenberg, RJ, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32: 2555–2562.
Google Scholar | Crossref | Medline46. Schurgers, LJ, Aebert, H, Vermeer, C, et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 2004; 104: 3231–3232.
Google Scholar | Crossref | Medline47. Price, PA, Faus, SA, Williamson, MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400–1407.
Google Scholar | Crossref | Medline48. Andrews, J, Psaltis, PJ, Bayturan, O, et al. Warfarin use is associated with progressive coronary arterial calcification: insights from serial intravascular ultrasound. JACC Cardiovasc Imaging 2018; 11: 1315–1323.
Google Scholar |